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Abstract
Background:  DBA/2J (D2) mice develop an age-related form of glaucoma. Their eyes
progressively develop iris pigment dispersion and iris atrophy followed by increased intraocular
pressure (IOP) and glaucomatous optic nerve damage. Mutant alleles of the Gpnmb and Tyrp1 genes
are necessary for the iris disease, but it is unknown whether alleles of other D2 gene(s) are
necessary for the distinct later stages of disease. We initiated a study of congenic strains to further
define the genetic requirements and disease mechanisms of the D2 glaucoma.
Results: To further understand D2 glaucoma, we created congenic strains of mice on the C57BL/
6J (B6) genetic background. B6 double-congenic mice carrying D2-derived Gpnmb  and  Tyrp1
mutations develop a D2-like iris disease. B6 single-congenics with only the Gpnmb and Tyrp1
mutations develop milder forms of iris disease. Genetic epistasis experiments introducing a B6
tyrosinase mutation into the congenic strains demonstrated that both the single and double-
congenic iris diseases are rescued by interruption of melanin synthesis. Importantly, our
experiments analyzing mice at ages up to 27 months indicate that the B6 double-congenic mice are
much less prone to IOP elevation and glaucoma than are D2 mice.
Conclusion: As demonstrated here, the Gpnmb and Tyrp1 iris phenotypes are both individually
dependent on tyrosinase function. These results support involvement of abnormal melanosomal
events in the diseases caused by each gene. In the context of the inbred D2 mouse strain, the
glaucoma phenotype is clearly influenced by more genes than just Gpnmb and Tyrp1. Despite the
outward similarity of pigment-dispersing iris disease between D2 and the B6 double-congenic mice,
the congenic mice are much less susceptible to developing high IOP and glaucoma. These new
congenic strains provide a valuable new resource for further studying the genetic and mechanistic
complexity of this form of glaucoma.
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Background
The glaucomas are a common group of diseases sharing a
characteristic pattern of retinal ganglion cell (RGC)
degeneration and optic nerve head excavation [1-3].
Increased intraocular pressure (IOP) is a significant pre-
disposing risk factor for glaucoma, and all current glau-
coma treatments aim to manipulate this trait [4,5].
Pigment dispersion syndrome (PDS) is a common condi-
tion that results in the dispersion of iris pigment into the
anterior chamber (AC) [6,7]. The dispersed pigment accu-
mulates within the ocular drainage structures, resulting in
IOP elevation and glaucoma in some but not all individ-
uals with PDS [8-12]. The molecular events that underlie
PDS and that determine whether pigment dispersion
leads to IOP elevation and pigmentary glaucoma remain
largely unknown. A promising approach for gaining
insight into these complex processes is to use the mouse
as an experimental system [13-16]. A benefit of this
approach is that genetic and environmental factors can be
significantly controlled and manipulated, thus making
the biological complexity of a disease such as glaucoma
easier to approach experimentally.
DBA/2J (D2) mice, and some related substrains, develop
a form of glaucoma characterized by a pigment-dispersing
iris disease that aberrantly deposits pigment throughout
the AC, including the drainage structures of the eye. As a
consequence, IOP becomes elevated and glaucomatous
RGC degeneration ensues [17-21]. The D2 iris disease is
initiated by the combined interactions of the Tyrp1b and
GpnmbR150X  mutations [22,23]. Tyrp1  encodes a mem-
brane-bound melanosomal protein with enzymatic activ-
ity involved in melanin synthesis [24-26]. Relatively little
is known about Gpnmb function. The GPNMB protein has
been detected in melanocytes [27], dendritic cells [28],
and a small list of other cell types [29-33]. Despite these
findings, the cellular mechanisms by which Tyrp1  and
Gpnmb  contribute to the glaucoma remain largely
unknown. Furthermore, it is also unknown whether the
Gpnmb and Tyrp1 mutations are sufficient to elicit the D2
form of glaucoma, or whether additional alleles are neces-
sary during distinct stages of disease.
Here, we report experiments utilizing an analysis of con-
genic strains of mice that further probe the genetic
requirements contributing to the D2 form of glaucoma.
The D2-derived Tyrp1b and  GpnmbR150X mutations were
backcrossed into the widely used C57BL/6J (B6) back-
ground. B6 double-congenic mice (homozygous for both
mutations) were utilized in genetic epistasis experiments
and compared with D2 with respect to clinical indices of
iris disease, IOP elevation, and optic nerve damage. Simi-
lar to D2 mice, B6 double-congenic mice develop a severe
depigmenting iris disease leading to massive pigment dis-
persion and aberrant pigment deposition on AC tissues.
In comparison to D2, the B6 double-congenic mice are
much less likely to develop increased IOP in response to
this pigment dispersing disease. These results indicate that
initiation (iris disease) and progression (high IOP) of
glaucomatous phenotypes in D2 mice are genetically sep-
arable and that additional D2-derived hereditary factors
relevant to glaucoma remain to be characterized. Identifi-
cation of these factors in mice may promote understand-
ing of factors contributing to human glaucoma and
suggest improved strategies for preventing glaucoma pro-
gression.
Results
Generation of B6 congenic strains containing the Tyrp1b 
and GpnmbR150X mutations
In order to further probe the genetic requirements con-
tributing to the D2 form of glaucoma, we created congenic
strains of mice on the B6 genetic background. Our
approach for transferring the D2-derived Tyrp1band
GpnmbR150X mutations to the B6 background was to first
create separate congenic strains for each of the respective
chromosomal regions (Figure 1). Successive rounds of
backcrossing utilizing markers flanking Tyrp1 (Figure 1A)
and Gpnmb (Figure 1B) yielded the single-congenic strains
for  Tyrp1b  (B6.D2-Tyrp1b/Sj; here after abbreviated
B6.Tyrp1b) and GpnmbR150X (B6.D2-GpnmbR150X /Sj; here
after abbreviated B6.GpnmbR150X). The final sizes of the
N10 congenic intervals were determined to be 14–36 cM
(23.6–63.2 Mb) for B6. Tyrp1b and 9–15 cM (10.0–36.8
Mb) for B6. GpnmbR150X. After each single N10 congenic
strain was established, mice were intercrossed to generate
a double-congenic stock homozygous for both congenic
intervals (B6.D2-Tyrp1bGpnmbR150X /Sj; here after abbrevi-
ated B6.Tyrp1b GpnmbR150X or referred to as B6 double-con-
genic).
B6 background is permissive to Tyrp1b and GpnmbR150X 
mediated iris disease
Cohorts of N10 mice of all three genotypes (B6.Tyrp1b, B6.
GpnmbR150X, and B6.Tyrp1bGpnmbR150X) were aged and
assayed for relevant phenotypes. As expected, congenic
mice homozygous for the Tyrp1bmutation had brown coat
colors [34,35], whereas the GpnmbR150X mutation had no
effect on coat color in any of the stocks examined. Clinical
analysis of iris phenotypes in aged cohorts of the single-
congenic B6.Tyrp1b  (Figs. 1C to 1E), single-congenic
B6.GpnmbR150X  (Figs. 1F to 1H), and double-congenic
B6.Tyrp1b GpnmbR150X (Figure 2) strains of mice indicated
that the B6 background was permissive to the iris disease.
Iris phenotypes of the single-congenic strains closely
resembled our previous observations of mice mutant for
only  Gpnmb  or  Tyrp1  in varying genetic contexts
[22,23,36]. Furthermore, the timing and severity of pig-
ment dispersing iris disease in the double-congenicBMC Biology 2006, 4:20 http://www.biomedcentral.com/1741-7007/4/20
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B6.Tyrp1bGpnmbR150X mice is essentially the same as in D2
mice mutant for the same Tyrp1 and Gpnmb alleles [19].
Pigmentary pathway contributes to Tyrp1 and Gpnmb 
mediated iris disease
We next took advantage of the B6 background to perform
strain controlled genetic epistasis experiments that tested
mechanisms contributing to the Tyrp1 and Gpnmb medi-
ated iris disease. A significant result in understanding the
Tyrp1 and Gpnmb mediated iris disease is that modulating
pigment production with tyrosinase (Tyr, a gene essential
for pigment production) and hypopigmentation muta-
tions completely rescues iris atrophy and pigment disper-
sion [22,23]. These experiments strongly implicated
melanosomal functions of Tyrp1 and Gpnmb in pathogen-
esis. However, they were not absolutely complete, since
only the effect of hypopigmentation mutations and not
Tyr were assessed for Gpnmb. This is important because
hypopigmentation mutations often affect multiple types
of organelles [37,38] whereas Tyr has no known function
in any organelles other than melanosomes.
To assess the importance of pigmentary pathways on the
B6 background, we used the Tyrc-2J mutation that arose
spontaneously in the B6 strain [39,40]. We generated
multiple cohorts of homozygous, Tyrc-2J albino mice that
were also homozygous for both Tyrp1b and GpnmbR150X
(Figure 3), or also homozygous for only Tyrp1b  or
GpnmbR150X  (data not shown). Aged cohorts of these
albino mice were compared with normally pigmented
mice of matched genotypes. All mice homozygous for the
Tyrc-2J mutation had albino coats (Figure 3A) and albino
The B6 genetic background is permissive to iris phenotypes individually caused by Tyrp1b and GpnmbR150X mutations Figure 1
The B6 genetic background is permissive to iris phenotypes individually caused by Tyrp1b and GpnmbR150X 
mutations. (A) The Tyrp1b and (B) the GpnmbR150X congenic intervals on chromosome 4 and chromosome 6. After 10 gener-
ations of backcrossing, the selected D2-derived intervals (filled red box), as well as a limited amount of flanking DNA (empty 
red box), were present in an essentially B6-derived background (thin blue line). The chromosome 4 interval is delimited prox-
imally by D4Mit214-D4Mit151 and distally by D4Mit185-D4Mit146; the chromosome 6 interval is delimited proximally by 
D6Mit268-D6Mit207 and distally by D6Mit277-D6Mit16. B6.Tyrp1b irides at (C) 4 months, (D) 9 months, and (E) 20 months. 
From 1–6 months, B6.Tyrp1b irides were indistinguishable from wild-type B6. Thereafter, B6.Tyrp1b eyes were characterized by 
a gradual atrophy of iris stromal morphology. Beginning at 6 months, a population of small phagocytic clump cells began to be 
discernible across the iris surface. With age, the underlying vasculature became obscured, and irides appeared increasingly 
coarse and atrophic, particularly at the pupil margin where a narrow white band of underlying tissue was exposed. With 
advanced age, full-thickness iris holes occurred, but rarely before 2 years of age (n = 16 eyes at 1–6 months, 20 eyes at 7–11 
months, and 42 eyes at 12+ months). B6.GpnmbR150X irides at (F) 4 months, (G) 9 months, and (H) 20 months. From 1–5 
months, B6.GpnmbR150X irides were indistinguishable from wild-type B6. Near 6 months, B6.GpnmbR150X eyes developed a pro-
nounced peripupillary swelling accompanied by pronounced accumulation of clump cells on the iris surface. These swellings 
remained prominent to the oldest ages examined. The iris surface maintained an overall normal morphology during the first 
year, after which time it became increasingly atrophic, and accumulations of dispersed pigment were visible on the lens and 
cornea. No sex-specific differences were evident in the phenotypes of either strain. (n = 16 eyes at 1–6 months, 20 eyes at 7–
11 months, and 46 eyes at 12+ months).BMC Biology 2006, 4:20 http://www.biomedcentral.com/1741-7007/4/20
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Severe iris disease in double-congenic B6. Tyrp1b GpnmbR150X mice Figure 2
Severe iris disease in double-congenic B6. Tyrp1b GpnmbR150X mice. Cohorts of B6.Tyrp1isa GpnmbR150X mice were aged 
and analyzed by slit-lamp examination; representative eyes of indicated ages are shown. Each row contains three images of the 
same eye. The left column shows broad-beam illumination. The middle column shows transillumination defects. The right col-
umn shows the relative dimensions of the anterior chamber. The degree of pigment dispersion and iris atrophy is remarkably 
similar in both timing and severity to that of D2 mice (see reference [19] for comparable image of D2 eyes). (A to C) Until 5 
months, B6.Tyrp1bGpnmbR150X eyes were indistinguishable from wild-type, with a complex iris morphology, no transillumina-
tion, and anterior chambers of normal dimension with a closely juxtaposed cornea and iris. (D to F) By 6 months, all B6.Tyrp1b 
GpnmbR150X eyes exhibit a clear phenotype characterized by slight swelling of peripupillary tissue. This timing and phenotype 
closely resembles the initial stages of the D2 iris disease. (G to I) In 9-month-old eyes, the peripupillary region becomes nota-
bly atrophic, transillumination is obvious, and dispersed pigment is present on both the lens and cornea. Beyond this age, a 
steadily worsening course ensues, which at (J to L) 12 months, (M to O) 14 months, and (P to R) 18 months is characterized 
by increasing degrees of iris atrophy that include full-thickness iris holes, profound transillumination, pigment dispersion and 
frequent pigment accumulation on the lens and cornea, and changes to the dimensions of the anterior chamber. No sex-spe-
cific differences were evident in these phenotypes. This synopsis of disease progression involved >146 eyes aged 2–20+ 
months, with each of the cohorts described above involving groups of at least 14 eyes.BMC Biology 2006, 4:20 http://www.biomedcentral.com/1741-7007/4/20
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irides (Figure 3B–G). Importantly, the Tyrc-2J mutation res-
cued all observable Tyrp1b – and GpnmbR150X-associated
iris phenotypes in double-congenic B6.Tyrp1b GpnmbR150X
mice (Figure 3C, E, and 3G) and single-congenic B6.Tyrp1b
(n = 28 eyes, 12+ months) and B6.GpnmbR150X mice (n = 8
eyes, 12+ months). These results convincingly indicate
that melanin production is a necessary component of the
pathological events initiating iris disease on a B6 back-
ground, and they confirm a melanosomal component for
both the Tyrp1 and Gpnmb mutant phenotypes.
B6. Tyrp1b and GpnmbR150X mice are less susceptible to 
IOP elevation than D2 mice
Having established that B6.Tyrp1bGpnmbR150X mice exhibit
a pigment-dispersing iris disease that is clinically, and
mechanistically, similar to that in D2 mice, we next tested
whether the B6 genetic background would influence the
impact of this insult on IOP. Although the timing and
severity of iris disease was similar, IOP elevation was sig-
nificantly muted in B6.Tyrp1bGpnmbR150X mice compared
with D2 mice (Figure 4). We compared the IOP distribu-
tions of these strains in relation to IOP values of 19
mmHg and 21 mmHg. As a strain, young D2 mice have
lower IOP than young B6 mice and 19 mmHg is > 2 SD
above the mean of young pre-glaucomatous D2 mice. The
value of 21 mmHg is glaucoma relevant, as individuals
with an IOP of 21 mmHg are commonly regarded as glau-
coma suspect [41]. Strikingly, a far smaller proportion of
B6.Tyrp1bGpnmbR150X mice were detected with IOP > 21
mmHg compared with D2 mice (Figure 4A to 4D). For
example, at 7–8 months only 2 % of B6.Tyrp1bGpnmbR150X
mice had IOP > 21 mmHg, compared with 16 % of D2
mice (P = 0.007,χ2 comparing number of mice with IOP <
19 mmHg, 19–21 mmHg, and > 21 mmHg for each strain
at this age). Similarly, at 9–10 months, only 11% of
B6.Tyrp1bGpnmbR150X  had IOPs >21 mmHg, compared
with 42 % of D2 (P < 0.0001, similar χ2 comparison for 9
to 10-months mice). The same trend was observed consid-
ering all mice, irrespective of age (P < 0.0001, χ2). Further
demonstrating their lower susceptibility to developing
high IOP, pressure elevation was delayed in
B6.Tyrp1bGpnmbR150X mice compared with D2 mice (Fig-
ure 4E and 4F). Whereas the greatest proportion of D2
mice had IOP > 21 mmHg (42%) at 9–10 months, the
greatest proportion of B6.Tyrp1bGpnmbR150X mice (16%)
had IOP > 21 4 months later at 13–14 months of age (P <
0.0001,  χ2  comparing B6.Tyrp1b  GpnmbR150X  at 13–14
months with D2 at 9–10 months). Therefore, as a popula-
tion, B6.Tyrp1bGpnmbR150X mice are less susceptible to IOP
elevation than D2 mice.
B6. Tyrp1b and GpnmbR150X mice do not develop 
glaucomatous nerve damage
The relatively low susceptibility of B6.Tyrp1b GpnmbR150X
mice to IOP elevation suggested that this strain may expe-
Tyrosinase deficiency prevents iris disease in B6. Tyrp1b  GpnmbR150X mice Figure 3
Tyrosinase deficiency prevents iris disease in B6. 
Tyrp1b GpnmbR150X mice. Intercrosses generated mice 
homozygous for various genotypic combinations of the 
Tyrp1b and GpnmbR150X mutations with the albino-inducing 
Tyrc-2J mutation. These mice were aged and analyzed by slit-
lamp examination; representative B6.Tyrp1b GpnmbR150X eyes 
are shown. (A) The normally brown pigmented coat of a 
mouse on the left compared with a triple homozygous Tyrc-2J 
Tyrp1b GpnmbR150X mouse on the right. (B, D, F) Different 
views emphasize the clinical morphology of the albino iris. 
Eyes of B6 mice that are homozygous for the Tyrc-2J mutation 
only appear pink as they lack melanin, but otherwise the iris 
and its vasculature have normal morphology. (C, E, G) 
Homozygosity for Tyrc-2J completely prevents iris disease in 
B6.Tyrp1b GpnmbR150X Tyrc-2J mice. The iris morphology of the 
triple mutant is indistinguishable from that of B6 mice 
homozygous for Tyrc-2J only (compare 3B to 3C), lacks 
peripupillary abnormalities (compare 3D to 3E), and has a 
healthy uninterrupted vasculature (3F to 3G). n = 14 eyes, all 
12+ months.BMC Biology 2006, 4:20 http://www.biomedcentral.com/1741-7007/4/20
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rience less glaucomatous nerve damage than D2 mice. In
D2 mice, severe glaucomatous damage with substantial
axon loss is detectable in over 50% of 11-month-old, 70%
of 13-month-old and 80% of 19-month-old mice [42,43].
In contrast, severe damage was almost never detected in
B6.Tyrp1b GpnmbR150X mice (Figure 5). At ages when 50–
80% of D2 mice have severe damage, only one of 109
B6.Tyrp1bGpnmbR150X nerves was severely affected (56 of
these nerves were from mice >18 months old). The distri-
B6.Tyrp1b GpnmbR150X mice have optic nerve phenotypes sim- ilar to standard B6 mice Figure 5
B6. Tyrp1b GpnmbR150X mice have optic nerve pheno-
types similar to standard B6 mice. Optic nerve cross-
sections were stained by the PPD method, which darkly 
stains the myelin sheath of all axons and the axoplasm only of 
diseased or dying axons. The majority of optic nerves had 
only the mild degree of damage that is typical for aged mice, 
as shown here in a comparison of optic nerves from: (A) typ-
ical 22-month-old B6, versus (B) typical 22-month-old 
B6.Tyrp1b GpnmbR150X. This was true even in mice with the 
highest IOPs recorded in the study, as shown here with (C) 
14-month-old B6.Tyrp1b GpnmbR150X and (D) 22-month-old 
B6.Tyrp1b GpnmbR150X. Scale bar = 10 μm. (E and F) The 
overall distribution of nerve damage was almost identical in 
both standard B6 and B6.Tyrp1b GpnmbR150X mice. Although 
some mice of each genotype developed a "moderate" degree 
of damage with age, the degree of damage in these mice only 
just met inclusion criteria for the "moderate" level and never 
involved significant axon loss. It was, therefore, much milder 
in all of these "moderate" mice than is typical of "moderate" 
D2 mice [42, 43]. A single B6.Tyrp1b GpnmbR150X nerve had 
severe damage. The similar damage distributions of both 
standard B6 and B6.Tyrp1b GpnmbR150X mice indicates that the 
damage reflects age-related B6 changes that are not related 
to Gpnmb and Tyrp1 glaucoma. For each group, the number 
of optic nerves graded for B6 and B6.Tyrp1bGpnmbR150X were: 
(4–6 months) 10 and 8, (11–12 months) 19 and 22, (13–15 
months) 29 and 38, (16–19 months) 28 and 28, (20–26 
months) 24 and 17. (E) Quantitative axon counts (mean ± 
SEM) show no detectable axon loss in B6.Tyrp1b GpnmbR150X 
compared with standard B6 mice. The similar damage distri-
butions and lack of axon loss in both strains indicates that the 
detected damage reflects age-related B6 changes that are not 
related to Gpnmb and Tyrp1 glaucoma. For each group, the 
number of randomly selected nerves utilized in quantitative 
axon counting for B6 and B6.Tyrp1bGpnmbR150X were: (4- 
months) 6 and 6, (22–27 months) 8 and 10.
B6.Tyrp1b GpnmbR150X mice are relatively resistant to IOP ele- vation Figure 4
B6.Tyrp1b GpnmbR150X mice are relatively resistant to 
IOP elevation. Graphs of IOP and age for D2 mice (left col-
umn) versus B6.Tyrp1b GpnmbR150X mice (right column), with 
the same data represented as: (A and B) bar graphs of mean 
IOP +/- SEM (>30 mice per bin), (C and D) scatter plots, 
and (E and F) plots showing percent of mice with IOP of 
indicated values. IOP was recorded from a total of 336 
B6.Tyrp1b GpnmbR150X mice and 1437 D2 mice. All groups 
contained >30 mice and included both male and female mice.BMC Biology 2006, 4:20 http://www.biomedcentral.com/1741-7007/4/20
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butions of nerve-damage level were almost identical in
B6.Tyrp1b GpnmbR150X and wild-type B6 mice (Figure 5),
indicating that the degree of damage in B6.Tyrp1b
GpnmbR150X mice represents standard aging changes for
this strain background. To maximize the likelihood of
detecting glaucoma, optic nerves from the mice with the
highest IOPs were examined (Figure 5C and 5D), but
none had a level of damage similar to the glaucomatous
damage of D2 mice. Additionally, no significant differ-
ence in the number of healthy axons was detected
between normal B6 and B6.Tyrp1isa GpnmbR150X mice aged
either 4–5 or 22–27 months (Figure 5G). Combined, the
analysis of optic nerves from these cohorts of B6.Tyrp1isa
GpnmbR150X  mice convincingly shows that on the B6
genetic background, the Tyrp-1 and Gpnmb-mediated iris
disease does not result in glaucoma.
Discussion
On a D2 background, mutations in Tyrp1  and  Gpnmb
underlie a form of pigmentary glaucoma involving a pig-
ment-dispersing iris disease, increased IOP, and optic-
nerve disease [18,19,22,23]. Here, we report transfer of
the D2-derived Tyrp1band GpnmbR150X mutations to the B6
genetic background to produce a B6 double-congenic
strain that develops the iris disease. Surprisingly, the B6
double-congenic mice were less susceptible to IOP eleva-
tion than D2 mice and did not develop glaucomatous
nerve damage. These strains provide a powerful resource
for studying the functions of Tyrp1 and Gpnmb, dissecting
the molecular mechanisms by which pigment dispersion
leads to IOP elevation, and identifying additional genes
contributing to the D2 form of glaucoma. Furthermore,
congenic strains are broadly useful resources, and these
strains will likely have additional benefit to the broader
mouse-genetics community [44].
Melanosomal processes contribute to both Gpnmb and 
Tyrp1 phenotypes
The current experiments demonstrate that melanosomal
defects associated with melanin synthesis play a key role
in the initiation of both Tyrp-1 and Gpnmb-mediated iris
disease. Melanosomal synthesis of melanin involves a
series of reactions creating the biopolymer melanin from
the precursor tyrosine [45]. Many of the indole-quinone
intermediates of these reactions are cytotoxic, and the
mechanisms regulating their cytotoxicity are only partially
understood [46,47]. Our results indicate that mutations
in Tyrp1 and Gpnmb act in the melanosome, where they
promote cytotoxicity in a manner that can be rescued by
halting production of these toxic intermediates. Based on
these findings, it will be important to examine other genes
encoding melanosomal proteins that may participate in
these events and that may also cause similar diseases of
the iris.
Genetic background affects susceptibility to IOP elevation 
and subsequent glaucoma
The experiments described above demonstrate that the
severity and timing of the pigment-dispersing iris disease
of B6 double-congenic mice is essentially the same as that
of D2 mice. This suggests that the dispersed pigment and
iris debris similarly insult the ocular drainage structures of
both strains. Nevertheless, the B6 double-congenic mice
were much less susceptible to IOP elevation than D2
mice. Probably because of their resistance to IOP eleva-
tion, the B6 double-congenics were not found to develop
glaucoma. In fact, the degree of optic-nerve damage
observed was largely similar to age-matched wild-type B6,
indicating that the small degree of optic neuropathy
observed was likely an independent phenomenon, such
as the result of the normal aging process or a low-pene-
trance developmental abnormality. Experiments to
understand this strain difference in IOP elevation are
underway.
These experiments also suggest that the cytotoxicity medi-
ated by Tyrp1 and Gpnmb does not kill the RGCs, and that
iris disease and RGC death can be dissociated from each
other. Therefore, RGC death in D2 mice appears to be a
pressure-dependent process resembling the pathology of
human glaucoma. In support of this, RGC death in this
model is not uniformly distributed [48,49], as would be
expected if damaged by an iris-derived diffusible toxin.
Rather, it appears that RGCs are uniquely susceptible reti-
nal neurons, and the pattern of damage is consistent with
an insult to RGC axons in the optic nerve [17,49].
Genetics and human PDS
The broader implications of the strain-specific pheno-
types may be important for studies of the heredity and
mechanism of human pigmentary glaucoma. In humans,
PDS/PG exhibits strong hereditary associations [50-52]. A
few families with clear inheritance of PDS are reported.
However, the low incidence of PDS in family members of
the majority of affected individuals suggests a more com-
plex etiology, possibly influenced by multiple genetic and
environmental factors. In some families, linkage was ini-
tially reported between the disease phenotype and mark-
ers on 7q35-q36 [50]. However, causative mutations at
this locus have thus far not been found. Analysis of candi-
date genes suggested by experiments with D2 mice (such
as TYRP1 and GPNMB) have also failed to identify any
clear mutations in these families [53]. Thus, the disease in
these families may be more complex than initially sus-
pected. The lack of identified mutations in GPNMB and
TYRP1 in these families does not preclude the involve-
ment of these genes (or genes of similar function) in
patients of other families or in the more common, more
complex cases. It remains to be determined whether PDS/
PG in other patient populations is caused by more tracta-BMC Biology 2006, 4:20 http://www.biomedcentral.com/1741-7007/4/20
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ble loci, or whether the identification of genes associated
with human PDS/PG may simply necessitate approaches
that can overcome genetic complexity.
Genetic context and human glaucoma
From a mechanistic view, the dichotomy between the dif-
fering responses of the B6 double-congenics versus D2
mice is analogous to the differing responses of people
with PDS. Many human eyes tolerate significant amounts
of dispersed pigment without developing glaucoma [6,7].
Indeed, fewer than half of human eyes with pigment dis-
persion progress to pigmentary glaucoma [8-12]. This,
along with the expected minor degree of aqueous humor
outflow obstruction due to pigment itself [54,55], sug-
gests that individual differences in the ocular reaction to
dispersed pigment are important in determining whether
pigment dispersion progresses to pigmentary glaucoma.
The D2 and B6 congenic strains provide a tractable
resource for mechanistically deciphering the ocular reac-
tions that determine whether IOP becomes harmfully ele-
vated after the drainage structures are insulted by
dispersed pigment and iris debris. Future studies of these
reactions will not only improve our mechanistic under-
standing of the disease, but may also suggest new classes
of genes worthy of analysis among human PDS/PG
patients.
Experimental implications of strain specific effects
Our results highlight the profound importance of genetic
background to complex diseases such as glaucoma. In
addition to understanding human glaucoma, it is impor-
tant to consider effects of genetic background when using
animal models. As a genetic resource, these congenic
mouse strains will help to address this issue. Until now, a
strain-matched control for Tyrp1 – and Gpnmb-mediated
disease has been problematic. For instance, although any
standard inbred mouse strain that does not develop glau-
coma can be utilized as a control for D2 mice, this exper-
imental design does not distinguish whether any observed
differences relate to the disease state of the eye, or are
merely previously unappreciated strain-dependent back-
ground effects. Given the complexity of these glaucoma
phenotypes, experiments comparing between different
strain backgrounds or using segregating backgrounds can
be misleading [13,56]. Importantly, the congenic mice
generated here can be utilized with strain-matched nor-
mal B6 mice to perform appropriately controlled experi-
ments.
Pressure-independent RGC death in C57BL/6 mice
Pressure-independent RGC death has been reported in
C57BL/6 mice and may depend on environment or sub-
strain used. In wild-type C57BL/6 mice from the supplier
Harlan (C57BL/6Hsd), an age-related reduction in the
number of RGCs has been described [48]. By 18 months,
the number of RGCs was reduced to approximately 46%
that of young mice. In our current study, this age-related
decline was absent in both the double-congenic B6.Tyrp1b
GpnmbR150X mice and normal B6 controls that all had a
C57BL/6J background. Similarly, we did not detect glau-
comatous RGC loss in another experiment where C57BL/
6J mice were also aged to 19+ months [57]. This difference
in RGC death between studies may be explained by poten-
tial environmental influences, differences in analysis pro-
tocols, or genetic differences in the substrain utilized.
Conclusion
This work introduces B6 congenic strains that allow
highly controlled experiments when studying glaucoma
resulting from the Tyrp1band  GpnmbR150X alleles. Using
this resource, we uncovered a striking strain dependence
of developing high IOP and glaucoma when challenged
by a profound pigment-dispersing iris disease. In future
experiments, it will be particularly important to identify
the pathways and genes influencing IOP elevation in this
setting.
Methods
Animal husbandry
Mice were obtained from The Jackson Laboratory (Bar
Harbor, ME, USA). All animals were treated according to
the guidelines of the Association for Research in Vision
and Ophthalmology for use of animals in research. All
experimental protocols were approved by the Animal
Care and Use Committee of The Jackson Laboratory. Data
for the congenic B6 strains are compared with those with
a D2 background. Many of the data for the D2 mice (more
than 1500 mice) have been previously reported but some
new IOP data are included here. The congenic B6 mice
were bred, aged and analyzed at the same time as over 300
D2 mice. The D2 mice were maintained on an NIH 31 diet
with a fat content of 6%. To avoid obesity, mice with a B6
background had to be maintained on essentially the same
NIH 31 diet but with a 4% fat content. Our studies have
shown that D2 IOP and other glaucoma phenotypes do
not differ with this small dietary difference (unpublished
data). For all mice, the diet was provided ad libitum, and
the water was acidified to pH 2.8–3.2. Mice were housed
in cages containing white-pine bedding and covered with
polyester filters. The environment was kept at 21°C with
a 14-hour light:10-hour dark cycle.
Generation of congenic strains and genotype analysis of 
congenic intervals
Chromosomal intervals of approximately 6–7 cM were
selected for the regions flanking Tyrp1  (D4Mit178  to
D4Mit327) and Gpnmb  (D6Mit74  to  D6Mit355). Mice
were reiteratively bred to B6 mice and each successive gen-
eration genotyped to select breeders heterozygous for the
respective D2 regions. This process was continued for 10BMC Biology 2006, 4:20 http://www.biomedcentral.com/1741-7007/4/20
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generations of backcrossing. At the 10th generation, mice
were intercrossed and each region bred to homozygosity.
Within the respective congenic intervals, the presence of
the  Tyrp1b allele was confirmed by assaying for a D2-
derived polymorphism creating a TaqI restriction-enzyme
site in exon 4 [35], and the presence of the GpnmbR150X
mutation was confirmed by assaying for a PvuII restric-
tion-enzyme site created by the D2-derived mutation [23].
The sizes of the congenic intervals were determined using
genomic DNA prepared from homozygous mice at the
10th generation of backcrossing and assayed using poly-
morphic microsatellite markers with standard PCR condi-
tions.
Intraocular pressure measurement
IOP was measured using the microneedle method as pre-
viously described in detail [58,59]. All cohorts included
male and female mice. Each mouse used in this study had
only a single IOP measurement. Thus, each age group
shown consists of cohorts of different individual mice.
Because the IOPs of B6 mice are very consistent, B6 mice
were interspersed with experimental mice during all
experiments as a methodological control to ensure proper
equipment calibration and performance. Statistical com-
parisons of IOP profiles generated from these strains uti-
lize nonparametric data comparisons, with data grouped
according to empirically set points relevant to these stud-
ies: 19 mmHg (i.e. > 2 SD above the mean for young pre-
glaucomatous D2 mice) and 21 mmHg (a value com-
monly regarded as glaucoma suspect in humans) [41].
Clinical and histologic analysis
Eyes were examined with a slit-lamp biomicroscope and
photographed with a 40× objective lens. Phenotypic
assessment of iris disease was determined by indices of iris
atrophy and dispersed pigment following previously
described criteria [18,22,23,60]. Transillumination
defects were also measured (transillumination is an assay
of iris disease whereby reflected light passing through
depigmented areas of iris tissue are visualized as red
light). However, because transillumination is influenced
by multiple strain-specific traits not controlled in these
studies (such as iris thickness), it was not the primary
means of following disease progression across different
genetic backgrounds.
Optic nerve cross sections were examined for glaucoma-
tous damage using a modified para-phenylenediamine
(PPD) staining protocol to stain the myelin sheath of all
axons and the axoplasma of damaged axons [61]. Optic
nerves were prepared for analysis by overnight fixation in
phosphate-buffered glutaraldehyde/paraformaldehyde
mixture at 4°C followed by overnight treatment in
osmium tetroxide at 4°C. After osmification, nerves were
rinsed twice for 10 minutes in 0.1 M phosphate buffer,
once in 0.1 M sodium-acetate buffer, and dehydrated in
graded ethanol concentrations. After embedding this tis-
sue in resin, 1-μm-thick sections were stained in 1% PPD
for 35–40 minutes.
Stained sections were compared using a previously
described qualitative grading scale (including assessments
of the approximate number of healthy axons, number of
damaged axons, and scarring associated with gliosis) and
used to perform quantitative axon counts [42,43]. The
grading scale has previously been validated by compari-
sons to axon counts [42,43]. Quantitative axon counts
imaged 18 non-overlapping fields at 1000× magnifica-
tion, which were evenly spread throughout the cross-sec-
tion of the nerve; the sum area of these fields was equal to
10% of the total nerve cross-sectional area. The majority
of optic nerves were collected from mice within 48 hours
of IOP measurement. Some mice with elevated IOPs were
additionally age determined prior to assessment of the
optic nerve. Each age group investigated contained sam-
ples from males and females, as well as left and right
nerves.
Genetic nomenclature and stocks
The official gene abbreviations, full gene names, alleles,
and stocks utilized in this study include the following. The
full name for the Gpnmb gene is glycoprotein (transmem-
brane) nmb. The ipd  allele of Gpnmb  results from the
R150X premature stop codon mutation, GpnmbR150X [23].
The full name for the Tyrp1 gene is tyrosinase-related pro-
tein 1. The b allele of Tyrp1 encodes two amino-acid sub-
stitutions, compared with the C57BL/6J-derived allele
[35]. This D2 allele is also referred to as isa in the mouse
genome database and elsewhere [22,23]. The DBA/2J
stock utilized here was stock number 000671 from The
Jackson Laboratory. The full name for the Tyr gene is tyro-
sinase. The c-2J mutation spontaneously arose within a
C57BL/6J colony, resulting in a R77L amino acid substitu-
tion and also changing alternative splicing of the tyrosi-
nase pre-mRNA [39,40]. The Tyrc-2J stock utilized here was
C57BL/6J-Tyrc-2J/J (stock 000058 from The Jackson Labo-
ratory).
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